Kura Oncology to Participate in Citi’s 12th Annual Biotech Conference
August 29 2017 - 7:30AM
Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage
biopharmaceutical company focused on the development of precision
medicines for oncology, today announced that Troy Wilson, Ph.D.,
J.D., President and Chief Executive Officer, will participate in a
panel discussion entitled “Precision Medicine in Oncology and Next
Generation Diagnostics” at Citi’s 12th Annual Biotech Conference,
in Boston on September 6, 2017. The panel is scheduled to
begin at 1:00 p.m. EDT (10:00 a.m. PDT).
A live audio webcast of the panel discussion will be available
in the Investors section of Kura Oncology's website at
www.kuraoncology.com, with an archived replay available for 30 days
following the event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The company’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways
where there is a strong scientific and clinical rationale to
improve outcomes by identifying those patients most likely to
benefit from treatment. Kura Oncology’s lead drug candidate is
tipifarnib, a farnesyl transferase inhibitor, which is currently
being studied in multiple Phase 2 clinical trials. Kura’s pipeline
also includes KO-947, an ERK inhibitor, currently in a Phase 1
trial, and KO-539, an inhibitor of the menin-MLL protein-protein
interaction, currently in preclinical testing. For additional
information about Kura Oncology, please visit the company’s website
at www.kuraoncology.com.
CONTACT INFORMATION
INVESTOR CONTACT:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
robert.uhl@westwicke.com
CORPORATE COMMUNICATIONS CONTACT:
Mark Corbae
Vice President
Canale Communications
(619) 849-5375
mark@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024